SCHEMBL5407613

SCHEMBL5407613

O=C(NS(=O)(=O)/C=C/c1ccccc1)c1ccc(C(F)(F)F)cc1C(F)(F)F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 1/20 0.53
FLT4 P35916 1/20 0.53
KDR P35968 1/20 0.53
AVPR2 P30518 1/20 0.51
GPR27 Q9NS67 1/20 0.51
CES2 O00748 1/20 0.47
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
GAA P10253 2/20 0.44
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
POLB P06746 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
PTGES2 Q9H7Z7 5/20 0.42
MAOB P27338 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5403851 0.88 FLT1 (0.66) FLT1FLT4KDRAVPR2GPR27
SCHEMBL4620007 0.88 KMT2A (0.47) FLT1FLT4KDRGAAKMT2A
SCHEMBL4620014 0.88 KMT2A (0.47) FLT1FLT4KDRGAAKMT2A
SCHEMBL5408840 0.88 FLT1 (0.56) FLT1FLT4KDRAVPR2GPR27
SCHEMBL5411202 0.87 FLT1 (0.49) FLT1FLT4KDRGAAKMT2A
SCHEMBL5411189 0.87 FLT1 (0.49) FLT1FLT4KDRGAAKMT2A
SCHEMBL5414308 0.87 GAA (0.43) FLT1FLT4KDRAVPR2GPR27
SCHEMBL5414304 0.87 GAA (0.43) FLT1FLT4KDRAVPR2GPR27
SCHEMBL4262721 0.87 FLT1 (0.47) FLT1FLT4KDRAVPR2GPR27
SCHEMBL5411911 0.85 FLT1 (0.46) FLT1FLT4KDRAVPR2GPR27

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US claimed
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270874-A1 Styrylsulfonamides STS, SULT1E1, BRCA1 FLT1 4126/4885FLT4 4438/4885KDR 4332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.